Abstract:Objective To explore the associations of glycated hemoglobin (HbA1c) with new lesions in acute stroke patients after reperfusion therapy.Methods In this retrospective study, seventy-four acute stroke patients who received reperfusion therapy in our hospital were analyzed. All patients underwent MR examination before therapy and after therapy within 24 h. Stroke subtype was classified according to TOAST criteria. The proportion of HbA1c elevation and other clinical data were collected. Statistical analysis was used to analyze the correlation between HbA1c and new lesions in acute stroke patients.Results A total of 74 acute stroke patients received reperfusion therapy. After reperfusion therapy, 44 patients (59.46%) had new lesions on MRI. New lesions group had higher HbA1c and proportion of elevated HbA1c than that in non-new lesions group [(6.09 ± 1.03) VS (5.50 ± 0.76), 43.18% VS 16.67%], the difference was statistically significant (P < 0.05). Of 44 patients with new lesions, 28 (63.64%) were new local lesions and 16 (36.36%) were new distant lesions. Compare with new local lesions group, patients with new distant lesions had significantly higher HbA1c and proportion of elevated HbA1c [(6.64 ± 0.87) VS (5.78 ± 0.99), 68.75% VS 28.57%] (P < 0.05). Spearman's rank correlation analysis revealed that HbA1c was positively correlated with new lesions (rs = 0.384, P < 0.05). Logistic analysis demonstrated that elevated HbA1c [b =1.751, Sb = 0.599, Wald χ2 = 6.867, R = 3.800 (95% CI: 1.227, 11.768)] were independently associated with new lesions (P < 0.05).Conclusions Detection of HbA1c before therapy can help to predict the new lesions in acute stroke patients.